<DOC>
	<DOCNO>NCT00079417</DOCNO>
	<brief_summary>This phase III trial study well give carboplatin vincristine together standard local ophthalmic therapy work treat child intraocular retinoblastoma . Drugs use chemotherapy , carboplatin vincristine , work different way stop tumor tumor divide stop grow die . It yet know whether neoadjuvant chemotherapy combine standard local ophthalmic therapy effective treat intraocular retinoblastoma .</brief_summary>
	<brief_title>Neoadjuvant Carboplatin Vincristine Standard Local Ophthalmic Therapy Treating Patients With Intraocular Retinoblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine 2-year event-free survival patient Group B intraocular retinoblastoma treat neoadjuvant chemoreduction comprise carboplatin vincristine standardize local ophthalmic therapy . SECONDARY OBJECTIVES : I . Determine response rate one course chemoreduction ( standardized local ophthalmic therapy ) patient . II . Correlate response rate event-free survival patient treat regimen . III . Determine incidence toxic effect patient treat regimen . OUTLINE : This multicenter study . Patients receive chemoreduction comprise carboplatin IV 60 minute follow vincristine IV 1-2 minute day 1 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After first course chemoreduction , patient undergo standardized local ophthalmic therapy comprise local laser therapy , cryotherapy , and/or radioactive plaque comprise iodine I 125 ruthenium Ru 106 . Patients follow every 3-4 week active tumor see minimum 3 ophthalmic exam anesthesia , every 6-8 week 3 year age , every 4-6 month 10 year age , annually thereafter .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Newly diagnose Group B intraocular retinoblastoma meeting 1 follow criterion : Group B tumor ( ) 1 eye Group B tumor ( ) eye Group A tumor 1 eye Group B tumor ( ) eye Group E tumor 1 eye enucleate Group B tumor ( ) remain eye time enucleation Group E tumor Defined International Classification System Intraocular Retinoblastoma follow : Group A : Small tumor ( ≤ 3 mm great dimension ) confine retina , away foveola disc meeting follow criterion : More 3 mm fovea More 1.5 mm optic disk Group B : Tumors 3 mm meeting follow criterion : Confined retina location Group A Tumor associate subretinal fluid &lt; 3 mm tumor margin subretinal seed Group E : Must ≥ 1 follow present : Tumor touch lens Tumor anterior anterior vitreous face involve ciliary body anterior segment Diffuse infiltrate retinoblastoma Neovascular glaucoma Opaque medium hemorrhage Tumor necrosis aseptic orbital cellulite Phthisis bulbi Confirmation diagnosis CT scan MRI brain orbit AND ophthalmologic evaluation anesthesia within past 3 week No choroidal and/or optic nerve invasion past lamina cribosa No evidence extraocular retinoblastoma clinically head orbital MRI and/or CT scan No tumor present histological exam cut end optic nerve Group E eye enucleate study entry Performance status ECOG 02 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2.5 time ULN age Creatinine clearance ( base Schwartz formula ) radioisotope glomerular filtration rate ≥ 70mL/min/1.73 m^2 No prior chemotherapy No concurrent chemotherapy No prior radiotherapy No concurrent radiotherapy , include intensitymodulated stereotactic , proton beam radiotherapy Prior enucleation one eye allow provided remain eye Group B No concurrent enucleation No prior local ophthalmic therapy retinoblastoma No prior therapy retinoblastoma No local therapy chemotherapy course 1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>